Binbay and colleagues6 prospectively compared short-term quality-of-life scores of 36 patients who were treated with either laparoscopic

selleck chemical radical prostatectomy or open retropubic radical prostatectomy. Different questionnaires were used to assess postoperative quality of life. The study showed that although patients who underwent laparoscopic prostatectomy expressed a more favorable attitude toward surgery in the early period, there was no significant difference in quality of life at 3 months after surgery between the 2 groups. Djavan and coworkers7 presented an update of the European Study on Radical Inhibitors,research,lifescience,medical Prostatectomy. The aim of the study was to evaluate the legacy and impact of preservation of the tip of the seminal vesicle during radical retropubic prostatectomy on potency and continence rates. The investigators concluded that preservation of the tip of the seminal vesicles Inhibitors,research,lifescience,medical significantly

increased post-radical prostatectomy potency rates without jeopardizing oncologic outcomes. T3 Prostate Cancer Prostate cancer patients with locally advanced disease and a PSA value of 20 ng/mL or higher are considered very-high-risk patients. For that reason, most will receive a combination of radiotherapy with hormonal treatment or hormonal Inhibitors,research,lifescience,medical therapy alone. Radical prostatectomy is not considered a valuable treatment option in this patient group. A Belgian study8 evaluated 133 patients with cT3-4N0-1 prostate cancer and a preoperative PSA value of 20 ng/mL or higher who underwent radical surgery at 4 institutions. The results Inhibitors,research,lifescience,medical showed that, in this very select high-risk prostate cancer population,

radical prostatectomy with or without adjuvant Inhibitors,research,lifescience,medical or salvage treatment provided very good long-term cancer-specific survival. The investigators pointed out that radical surgery should not be ignored as a first step in a multimodality approach for very-high-risk prostate cancer. Djavan and coworkers9 evaluated oncologic outcomes of radical prostatectomy and radiotherapy in men with cT3 prostate cancer. The outcome of the study showed clearly that men with cT3 prostate cancer represent a largely inhomogeneous cohort. Disease-specific survival and cancer-specific survival were significantly lower than with cT2 disease. Furthermore, Mannose-binding protein-associated serine protease it was shown that treatment allocation and selection should be made on the basis of Gleason score, PSA value, and age. Age remains an independent and strong predictor of outcome. Interesting conclusions could be found at 5 and 10 years’ follow-up. First, in highly selected men with cT3 prostate cancer, radical prostatectomy offers an effective treatment option. Second, in men with cT3, Gleason score less than 7, and a PSA value of 4 to 10, external beam radiotherapy plus hormonal therapy is equally as effective as radical prostatectomy.